Sartorius Stedim Biotech reveals its results for the first quarter of 2024

Sartorius Stedim Biotech published its unaudited results for the first quarter of 2024, marked by a drop in its turnover and an increase in its order intake. Revenue reached €667 million, down 6.7% at constant exchange rate, while order intake increased by 13.9%, amounting to €676 million. Current EBITDA is 191 million euros with a margin of 28.6%. The net result stands at 56 million euros.

Responding to a challenging market environment, the company maintained its guidance for the current fiscal year, anticipating mid-to-high single-digit revenue growth. Despite significant challenges particularly in China and Europe, the company's activities have shown signs of recovery, particularly in the consumables and cell and gene therapies sector. The group expects a gradual improvement in its activity over the quarters, despite a context of increased geopolitical tensions and economic slowdowns.